4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Voyager Therapeutics, Inc. (VYGR) operates in the Biotechnology industry and is headquartered in Lexington, United States with about 141 employees. Its market capitalization is roughly $222 million. In the fiscal year ended 2025-12-31, VYGR reported $40M in revenue and ($120M) in net income.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Interactive charts & full statements → Open the VYGR valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $40M | $80M | $250M | $41M |
| Operating Income (EBIT) | ($132M) | ($83M) | $122M | ($51M) |
| Net Income | ($120M) | ($65M) | $132M | ($46M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $3M | $15M | $13M | $5M | $6M |
| Operating Income (EBIT) | ($30M) | ($30M) | ($31M) | ($37M) | ($35M) |
| Net Income | ($28M) | ($27M) | ($28M) | ($33M) | ($31M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $252M | $393M | $351M | $159M | — |
| Total Liabilities | $56M | $93M | $115M | $100M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VYGR viewer.
About TickerBase · Data methodology & sources